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• Prostanoids/eicosanoids are a group of lipid-soluble 
compounds which are produced by almost every cell in our 
body. They play a vital role in the proper functioning of organs. 
A deviation from the constant rate of formation and release 
ofprostanoids may lead to pathological situations, sometimes 
life-threatening. The realization that prevention of chronic 
diseases by dietary modification would be more effective and 
economically viable in large population than costly treatment 
with drugs and hospitalization has stimulated a general inter- 
est in the preventive effects of various dietary components, 
including vegetables, herbs and spices. In Ayurveda, various 
spices and herbs are described to show medicinal effects, such 
as anti-thrombotic, anti-atherosclerotic, hypoglycaemic, 
hypolipidaemic, anti-inflammatory, anti-arthritic etc. 
Furthermore, as spices modulate eicosanoidproduction they 
may serve to provide clue(s) to drugs directed to arachidon- 
ic acid pathway enzymes as pharmacological targets. Effects 
of aqueous or ethanolic extracts of few common spices (gar- 
lic, onion, ginger, clove, turmeric, cumin and omum) and 
some pure components isolated from them on in vitro platelet 
aggregation and their effects on prostanoid production are 
described. In some preliminary studies consumption of gin- 
ger and turmeric has been shown to ameliorate arihitric dis- 
eases, while ginger consumption is also shown to exert abortive 
and prophylactic effects in migraine headache. We propose 
that search for safe drugs from commonly used spices may 
open an interesting area in drug research. 
• Spices and herbs are dried parts of different kinds 
of plants grown for their aromatic, pungent or other desir- 
able substances. They include rhizomes, bulbs, barks, gum, 
flowerbuds, stigmas, fruits, seeds and leaves. They are char- 
acterized by loose terms such as spices, spice seeds, and 
herbs. Spices are fragrant or pungent plant products of 
tropical and subtropical regions. Spice seeds are the tiny 
aromatic fruits and oil containing seeds of herbaceous 
plants. Herbs are the fragrant leaves of such plants as mar- 
joram, mint, rosemary and thyme. It is not known when 
man first used spices and herbs in food. As they originate 
from the tropical and subtropical areas, it is very likely that 
they were used to impart durability to food. Food is main- 
ly spoiled by microbial growth. Rancidity of fat constituents 
of the food is another important factor contributing to food 
spoilage. Food prepared with spices (and herbs) stay longer 
due to their effects against growth of microorganisms and 
fat-rancidity. Several spices are known to contain antiox- 
idants which might contribute to the latter effect. 
Spices, spice seeds and herbs are added to food or used in 
food preparation with an intent purpose of imparting 
flavour and aroma to it. In the small quantities they are 
used in culinary practice, they are considered to provide 
little or no nutritive value. They, however, stimulate the 




may be additional benefits too. Use of spices in the recent 
year has spread to many cultures. This has generated some 
sort of curiosity to know more about them especially in 
relation to their biological effects and their modes of action 
in our body. The illustrious example of garlic may serve to 
underscore this point. It was used in several ancient cul- 
tures for centuries both as food and medicine. Inspite of 
that, it was only recently that the scientific community has 
taken garlic seriously. During the last two decades or so, 
evidence has been produced substantiating the claims 
made in the folklore. 
It might surprise many of us about what has been discov- 
ered concerning foods during this century. The foods are 
full of pharmacological agents, they do act as drugs in the 
body, and depending on the food one eats, effects at the 
cellular level can be demonstrated. Many of the food folk- 
lores are full of wisdom, and are being confirmed by mod- 
ern scientific methods. Clues from food folklore have 
inspired well-known scientists to investigate food-health- 
disease connections which has led to the realization of 
amazing powers in the food pharmacy. For example, fruits 
containing vitamin C were considered to prevent the scurvy 
in the earlier part of this century but now this vitamin is 
needed to maintain optimal health and the prevention of 
some chronic disease(s). Spices described below are not 
expensive and if their inclusion in the diet could be proven 
to delay/ward off the onset of chronic diseases (arthritis, 
atherosclerosis and cancer) billions of dollars could be 
saved in the health care systems. 
In Ayurveda (the traditional Indian system of medicine) 
and the Graeco-Arabic (Tibb) system of medicine, sever- 
al spices and herbs are described having medicinal effects, 
such as being anti-thrombotic, anti-atherosclerotic, 
hipolipidemic, hypoglycemic, anti-inflammatory, anti- 
arthritic etc. There are parallels existing between the 
involvement of eicosanoids in many pathological condi- 
tions and the claims in Ayurveda that spices and herbs can 
cure many of the same diseases. As spices modulate 
eicosanoid production they may serve to provide clue(s) 
to drugs directed to arachidonic acid pathways as phar- 
macological targets. 
EICOSANOIDS: PHYSIOLOGICAL, 
PHARMACOLOGI- CAL AHD CLINICAL 
RELEVANCE 
• Prostanoids are unsaturated lipids derived from 
fatty acid precursors such as arachidonic acid (AA) which 
is most abundant in the mammalian tissues compared to 
other precursors (dihomo-gamma-linolenic acid and eicos- 
apentaenoic acid). The term prostanoids includes a group 
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prostaglandins and thromboxanes. In mammalian tissues 
are synthesized over 20 different prostanoids each with 
varying biological activity. Even in a single organ, such as 
the lung or kidney a host of different prostanoids with sim- 
ilar or opposing and at times with no action in that par- 
ticular organ may be produced. To this list have been added 
a new group of biologically active substances called 
leukotrienes which are also synthesized from the same pre- 
cursors as for prostaglandins. The term eicosanoids was 
introduced by Corey et al. (1) to encompass 
prostaglandins, thromboxanes, prostacyclins, hydroper- 
oxy- and hydroxyeicosatetraenoic acids (HPETEs, 
HETEs), the leukotrienes and lipoxins. 
Almost all the mammalian tissues examined so far are 
known to produce one or the other kind of eicosanoids 
exibiting specific biological actions. As for example, 
prostanoids and leukotrienes have important actions in the 
cardiovacular system regulating the functions of the heart 
and coronary blood vessels, and blood pressure. 
Prostanoids are involved not only in the regulation of car- 
diovascular functions but are implicated in the patho- 
physiological conditions of this system as well. Similarly, 
prostaglandins have been shown to influence virtually 
every aspect of female reproductive functions including 
the release of gonadotrophic hormones from the pituitary 
gland, luteolysis (destruction of corpus luteum), menstru- 
ation, fertilization of the egg and implantation, parturition, 
lactation etc. In the gut, prostanoids are known to perform 
three major physiological functions: control of gut motili- 
ty, control of gastrointestinal secretions, and providing 
cytoprotection (protection against ulcers). Prostanoids 
show a direct action on the nephron to stimulate water and 
electrolyte reabsorption. They also influence renal func- 
tion by altering the blood flow within the kidney and by 
affecting the activity of renal sympathetic nevers. 
Furthermore, they interact with hormones such as 
angiotensin II, bradykinin and vasopressin (anti-diuretic 
hormone, ADH) which influence water and ion transport 
in this organ. Thus, it would not be surprising that an imbal- 
ance in the production of prostanoids should result in dis- 
eases of this organ (e.g., Barrier's syndrome due to ele- 
vated renal prostanoid - PGE2, PGD2, PG^- production; 
hepatorenal syndrome due to elevated TxA2 production). 
Considerable evidence has accumulated implicating 
prostanoids as mediators of inflammation and in diseases 
of inflammation (rheumatoid arthritis). Moreover, 
leukotrienes are considered to be involed in several patho- 
physiological processes such as, generalized or local 
immune reactions, i.e., psoriasis, inflammatory diseases, 
and in asthma, shock and trauma. Even neurological dis- 
eases like migraine, epilepsy and schizophrenia are condi- 
tions where prostaglandins are associated. Thus, the list of 
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Figure 1. An outline of the cydooxygenase catalyzed conver- 
sion of arachidonic acid into the pivotal intermediates - 
prostaglandin endoperoxides (PGG2 and PGH2> - together 
with other AA metabolites: thromboxane, prostaglandins and 
prostacyclin produced therefrom, and 12-lipoxygenase-derived 
products. I Thromboxane synthase; II Prostacyclin synthase; 
III PG-endoperoxide E isomerase; IV Prostaglandin F reduc- 
tase; V PG-endoperoxide D isomerase (From: Mustafa T and 
Srivaslava KC. Prostaglandins (eicosanoids) and their role in 
ectothermic organisms, p. 157 In: Advances in Comparative 
and Environmental Physiology, Vol. 5, Springer-Verlag, Berlin 
Heidelberg 1989) 
PROSTANOIDS AND PLATELETS 
• Platelets are small particles which circulate in the 
blood of mammals. Naturally, they appear as disc-shaped, 
roughly about 2-3 pm in diameter and 0.7 Mm in thickness. 
Human blood contains about 150000 - 400000 platelets per 
microliter. They play an important role in cardiovascular 
haemostasis. The major function of the blood platelets is 
to maintain the haemostatic integrity of the blood vessel 
and to stop bleeding after injury. To achieve this, platelets 
interact with the subendothelial components of the vessel 
wall, such as collagen, that activate the platelets in which 
it brings about a series of changes ranging from change of 
shape (from discoidal to spherical form), production of 
pseudopodia and adherence to collagen fibrils. The 
platelets in this acivated state release substances from their 
storage granules that cause other platelets to form aggre- 
gates at the site of the injury. This haemostatic plug is 
reversible and thus unstable. Stability is confirmed through 
activation of a coagulation system generating thrombin 
which produces insoluble fibrin from fibrinogen. It is the 
generation of fibrin that stabilizes the plug. Several steps 
of the coagulation cascade are dependent on the stimu- 
lated platelets for optimal activity. 
On stimulation platelets exhibit six responses: shape 
change, aggregation, arachidonic acid liberation, a-gran- 
ule release, dense granule release, and acid hidrolase 
release. The platelet responses are distinguishable on the 
basis of requirement for different concentrations of the 
aggregating agent. The concentration requirement 
increases for various responses in the above mentioned 
order. On the basis of strength, aggregation producing 
agents are divided into groups. ADP, adrenaline, nor-epi- 
nephrine, vasopressin and serotonin are weak activators 
capable of triggering only shape change and aggregation. 
Thromboxane A.2 (formed from liberated AA) is of an 
intermediate strength, and produces not only shape change 
and aggregation, but also the release of contens from the 
alpha- and dense granules. Thrombin, collagen (applies to 
platelets that actually adhere to it) and divalent ionophore 
A23187 (a non-physiological stimulus) are characterized 
as strong inducers that can produce all the six responses. 
When platelets are challenged with an aggregating agent 
(ADP, adrenaline, thrombin, collagen or calcium 
ionophore A23187) irreversible aggregation takes place 
accompanied by release of the contents of platelet storage 
granules. However, when platelets are challenged by strong 
inducers such as collagen, calcium ionophore A23187 or 
thrombin, a rapid deacylation of platelet phospholipids 
takes place. This results in the generation of free AA which 
is quickly metabolized to eicosanoids. In the case of stim- 
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pathophysiological conditions where eicosanoids play role 
is long. It is very likely that more information on this count 
would be added in the future. 
A general outline on the bioconversion of arachidonic acid 
into prostaglandins and some other AA metabolites is 
shown in Fig. 1. 
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uli, such as collagen and thrombin which activate platelets 
by a receptor-mediated mechanism, the story is not so sim- 
ple in regard to the release of AA. Phospholipase C is acti- 
vated following the activation of a receptor via G protein. 
It causes hydrolysis of the minor membrane lipid phos- 
phatidyl inositol-4,5-biphosphate (PIP2). The two prod- 
ucts of this hydrolysis are inositol 1,4,5-triphosphate (IP3) 
and 1,2-diacylglycerol (DAG). IP3 acts to mobilize intra- 
cellular calcium, and DAG stimulates the same protein 
kinase C that can be activated by tumor promoting phor- 
bol esters (2). IPg and DAG are considered second mes- 
sengers in this transduction mechanism. Thus, involvement 
of inositol which is uniquely rich in stearic acid at the - 
position and AA at the -position, a coupled system of phos- 
pholipase C and diglyceride lipase has assumed a greater 
significance in eicosanoid biosynthesis. It is likely that spe- 
cific stimuli induce eicosanoid production by the activa- 
tion of phospholipase C, whereas in pathophysiological sit- 
uations unspecific stimuli induce the formation of these 
compounds in which phospholise A2 is involed. However, 
platelet agonists like ADP and adrenaline, though capable 
of producing irreversible aggregation, do not generate 
large amounts of eicosanoids. Thus, in the case of ADP 
undetectable amounts of eicosanoids are generated, and 
with adrenaline as agonist very small amounts of these are 
produced (3). 
The liberated AA is converted by the enzyme cyclooxyge- 
nase first into pivotal compounds of the AA cascade, 
prostaglandin-endoperoxides (PGG2, PGH2) which 
involves incorporation of two moles oxygen per mole of 
AA. This reaction is known as the "oxygen-burst" when 
oxygen consumption of stimulated platelets is monitored 
(4). Prostaglandin-endoperoxides are short-lived AA- 
metabolites with a biological half-life of 5 min. Finally they 
end up in small amounts of stable metabolites called pri- 
mary prostaglandins (PGE2, PGF2a, PGD2). In the 
platelets, PG-endoperoxides are converted mainly to 
another class of eicosanoids - thromboxanes (Tx) pro- 
duced by a specific enzyme thromboxane synthase. 
Thromboxane A2 (TxA2) is a very potent aggregating 
agent, and contracts aorta and other blood vessel prepa- 
rations. TxA2 is very unstable with a biological half-life of 
about 30 seconds (5). Both TxA2 and PG-endoperoxides 
inhibit elevation of the platelet c-AMP levels by natural 
and physiological agents PGE^ and PGI2 without affect- 
ing the basal levels of c-AMP. Increased intracellular c- 
AMP inhibits aggregation by preventing mobilization of 
intracellular Ca^+ from the platelet dense tubular system 
or by phosphorylating specific proteins catalyzed by c- 
AMP-dependent protein kinases. Prostacyclin, a very 
potent antiplateled and blood vessel relaxing substance of 
physiological origin, is also a product of AA metabolism. 
It is produced from PG-endoperoxides by a specific 
enzyme called prostacyclin synthase localized mainly in the 
blood vessels (6). Antiplatelet activity of prostacyclin is 
affected through increased c-AMP levels. 
Physiologically important platelet aggregating agents in 
vivo include collagen, thrombin, ADP and possibly adren- 
aline and platelet activating factor (PAF). Collagen, 
thrombin and adrenaline are considered 'first messengers' 
causing platelet aggregation which is further increased by 
one or more of the 'second messengers', i.e., ADP released 
from dense granules or PGG2/TxA2 or PAF synthesized 
during platelet aggregation process. All the three 'second 
messengers' are considered to cause mobilization of 
sequestered Ca^+ from the intracellular stores which is 
related to decreased levels of c-AMP in the platelets (7) 
(Fig.2). Cyclic AMP stimulates calcium uptake by the 
dense tubular system and its extrusion from the platelets. 
In contrast, cyclic GMP opposses these two processes con- 




Figure 2. Three-tier mechanism of platelet aggregation. 
ROLE OF PLATELETS IN THROMBOSIS AMD 
ATHEROSCLEROSIS 
• Atherosclerosis and thrombosis are the major 
cause of death in the affluent societies. Of the several fac- 
tors that are considered to contribute to its development, 
diet is the most important one. In such societies, a major 
part of the dietary energy is provided by fat which comes 
chiefly from the animal products. A high fat intake may 
cause serum cholesterol and plasma fibrinogen levels to   
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increase, simultaneously decreasing the fibrinolytic activ- 
ity and blood coagulation time. It has become more and 
more established in recent years that platelets play a key 
role in the development of atherosclerosis. The concept of 
the "loss of endothelial integrity" is very tenable (8). There 
may be several causes producing endothelial damage. 
Mechanical forces at the sites of flow effect, cholesterol 
deposition and foam cell infiltration into the subendothe- 
lium, vasculitis due to toxins or bacterial or viral infections, 
and causes related to immunology are the important ones. 
Endothelial injury (loss of endothelium) leads to the expo- 
sure of subendothelial collagen to circulating blood cells, 
and the accumulation of macrophages and platelets at the 
site of injury. In this process, platelets secrete many chem- 
icals, including vasoactive substances and platelet-derived 
growth factor (PGDF) of which the latter induces the pro- 
liferation and migration of smooth muscle cells with the 
result a proliferative atherosclerotic lesion appears. In 
addition, two important observations made in animals 
serve to provide evidence for the role of platelets in ath- 
erosclerosis. Drastic reduction of platelet number before 
ballooning prevented subsequent thickening of the aortic 
wall in rabbits. And in a strain of pigs with severe von 
Willebrand's disease experimentally induced atheroscle- 
rosis was not produced, unlike normal pigs, when given a 
diet high in choresterol. From this it may imply that in the 
absence of von Willebrand factor the platelets did not 
adhere to the cholesterol-damaged arterial wall. However, 
there may be other stimuli contributing to this process. 
Lymphokines from different sources and growth factors 
derived from the endothelium and other cells of the ves- 
sel wall may play an equally improtant role. The evidence 
that platelets directly enhanced cholesterol esterification 
and macrophage cholesterol ester accumulation further 
underscores the important role platelets play in the devel- 
opment of atherosclerosis (9). 
The fundamental lesion in more than 95% of all cases of 
coronary heart disease (CHD) is coronary atherosclerosis 
which is a universal process occurring in most humans and 
is characterized by a local manifestation of a generalized 
disease. It may begin at quite an early age (10 yr) as fatty 
streaks and develop into progressive atheroma from the 
time of adolescence. Coronary atheroma may behave in 
either of the two ways: in some individuals it may remain 
clinically silent throughout life but in others it may devel- 
op into CHD which results from the narrowing and occlu- 
sion of the coronary artery. Therefore, the problem con- 
cerning the prevention of clinical coronary artery disease 
has two aspects: (i) prevention of occurrence of atheroma 
and its progression, and (ii) protection against complica- 
tions resulting from thrombosis. 
PLATELET AGGREGATION 
• Since in the present review, one of the essential 
features is the effects of spices on platelet aggregation and 
  
Figure 3. A typical platelet aggregation 
pattern induced by ADP showing 
reversible and irreversible phases of 
aggregation (left) with associated 
changes in platelets (right). A platelet 
aggregometeris used to study aggregation 
based on a simple photometric principle. 
As platelets aggregate increase in light 
transmission takes place, (a) Normal, 
unstimulated disc-shaped platelets with 
a variable number of organelles ran- 
domly distributed in the cytoplasm 
enclosed by a plasma membrane; (b) 
platelet shape change with associated 
pseudopodia; (c) primary aggregation in 




which are considered loose, hence unsta- 
ble; (d) platelets move apart (reversible 
aggregation); (e) platelets undergo sec- 
ondary (irreversible) aggregation follow- 
ing the release of proaggregatoiy agents 
from platelet granules. 
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the mechanisms by which this is affected, a brief descrip- 
tion of the various pathways involved in platelet aggrega- 
tion would be appropriate. The platelet function is depen- 
dent on several inter-dependent pathways which can be 
selectively inhibited without blocking platelet function. 
Thus, even though treatment of platelets with aspirin results 
in irreversible inhibition of the enzyme cyclooxygenase 
(reduced formation of TxA2), the platelets can be induced 
to aggregate and release their contents when challenged 
with higher concentrations of collagen and thrombin. 
Thromboxane A.^ produced in the platelets promotes 
release of ADP which concomitantly acts on the platelets 
in concert with TxA2- Removal of ADP enzymatically fol- 
lowed by treatment of platelets with aspirin can not block 
the platelet function, because such platelets still respond 
to thrombin. The mediator which produces aggregation in 
these platelets is termed platelet activating factor (PAF, a 
biologically active phospholipid, 1-O-alkyl, 2-acetyl, glyc- 
eryl-3-phosphocholine). PAF is generated by the action of 
thrombin, collagen or A23187 on human platelets. In con- 
trast, AA and ADP do not trigger its formation (10). Thus, 
three different pathways of platelet aggregation have been 
characterized: (i) thromboxane A2-dependent, (ii) ADP- 
dependent, and (iii) PAF-mediated. A typical aggregation 
pattern induced by ADP showing reversible and irre- 
versible aggregation with associated changes in platelets is 
shown in Fig. 3. 
PHARMACOLOGICAL EFFECTS OF SPICES 
• Effects of some common food spices on platelet 
aggregation and eicosanoid formation in human blood 
platelets have been reviewed earlier (11,12). Their effects 
on the generation of eicosanoids and the steps of the AA 
cascade in platelets where they show effect are shown in 
Fig. 4. Although the exact mechanisms by which these 
spices ellicit their medicinal effects are not fully known, 
their in vitro and in some cases ex vitro effects on platelet 
aggregation and on AA metabolism may suggest that, at 
least, one of the mechanisms could be related to their 
effects on the formation of eicosanoids whose role in sev- 
eral pathophysiological states is being realized. 
Below we give in some detail the pharmacological effects 
of some selected spices together with the active compo- 
nents contained therein and their effects on the enzymes 
of the AA cascade. 
 Garlic (Allium sativum)                                  
Garlic has been extensively studied for its effects in the 
cardiovascular system. The folklore that it thins the blood 
has been confirmed in several studies. We, as well as oth- 
 
Thromboxane B, 
Figure 4. Transformations of arachidonic acid in human 
platelets and the steps where spices show their inhibitory efects. 
Arachidonc acid esterified in the ^-position of the platelet mem- 
brane phospholipids is released by the action of phospholipase 
A^C on stimulation of platelets with an agonist. J2-HPETE, 
12-hydroperoxyeicosatetraenoic acid; J2-HETE, 12-hydroxye- 
icosatetraeonic add; 12-HHT, 12-hydroxyheptadecatrienoic 
acid; MDA, malondialdehyde; PGG^ 15-hydroperoxy-9,Jl- 
endoperoxide; PGH^ 15-hydroxy-9,ll-endoperoxide;Q inhi- 
bition. (From ref. 12) 
ers, have shown that both aqueous and organic extracts of 
garlic inhibit platelet aggregation-induced by AA, ADP, 
adrenaline, collagen, calcium ionophore A23187, throm- 
bin etc (13-15). Several mechanisms seem to be involved 
in this inhibitory effect of garlic. And, they include modi- 
fication of platelet membrane properties, inhibition of cal- 
cium mobilization, and inhibition of several steps of the 
AA-cascade in platelets. Thus, it was shown that garlic 
extracts inhibited incorporation of labelled AA in platelet 
phospholipids and also the deacylation of platelet phos- 
pholipids induced by calcium ionophore A23187. Inhibited 
phospholipid deacylation results in reduced amounts of 
free AA to be metabolized, as a consequence of which less 
eicosanoid production would take place. This has been 
observed by us (13,14). A direct inhibitory effect of garlic   
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extracts and its components on the enzymes of the AA cas- 
cade has also been reported (13,14,16,17). 
On examining the effects of methanolic extract of garlic 
and some pure fractions obtained therefrom, it was found 
that though the extract and its components inhibited 
platelet aggregation, they failed to modify the metabolism 
of AA in platelets (15). However, the methanolic extract 
and a pure fraction isolated from it did inhibit by more 
than of TxE$2 formation in collagen-stimulated platelets. 
The anti-platelet behavior of garlic and especially of one 
of its components (E,Z)-ajoene is, according to the 
authors, apparently due to its ability to create membrane 
perturbation achieved by deep insertion of this substance 
in between the two monolayers of plasma membranes of 
the intact platelets (Apitz-Castro, personal communica- 
tion). Ajoene did not alter AA metabolism in intact 
platelets. 
While it is probable that garlic modifies platelet membrane 
properties as inferred from the restricted entry of labelled 
AA into platelets (13,15), there are several studies report- 
ed by various groups which indicate that garlic extracts and 
some of its components, including (E,Z)-ajoene, modify 
AA metabolism in platelets and other biological systems 
containing the enzymes (including 5-lipoxygenase) of the 
AA cascade (13,16,17). Moreover, aqueous extract of gar- 
lic when administered to rabbits was found to inhibit TxA2 
formation in clotting blood and also in blood vessel prepa- 
rations of this animal. Interestingly, this treatment did not 
affect the generation of prostacyclin in whole blood and 
aortic tissue (18). In another study, pretreatment of rab- 
bits with an aqueous extract of garlic provided protection 
against thrombocytopenia and hypotension on adminis- 
tering collagen or arachidonic acid intravenously. The 
amount of thromboxane synthesized in these animals was 
reduced to levels not sufficient to induce thrombocytope- 
nia and hypotension. All animals that were pretreated with 
garlic survived against the lethal dose of collagen or AA 
(19). 
Intact and undisturbed bulbs of garlic contain only a few 
medicinally active compounds. Treatments like chopping, 
steaming of food processing brings about a radical change 
in the chemistry of garlic; the nature of the compounds 
produced depends largely on the mode garlic is handled. 
Crushing triggers the formation of a cascade of compounds 
that are quite reactive and take part in a complex system 
of chemical reactions. In such a process at least 100 sul- 
phur-containing compounds are produced. Garlic sulphur 
compounds are linked to its medicinal uses. 
Thus, the biological activity of an extract of garlic would 
depend on the mode of its preparation. The extract pre- 
pared at room temperature consists mainly of allicin, an 
antibacterial component. Allicin is unstable at room tem- 
perature with a half-life of ca. 2.4 hours. It is generated 
instantly when garlic is chopped or crushed due to the 
action of an enzyme called alliinase on the parent com- 
pound alliin, which is otherwise odourfree. Besides allicin, 
are also present small amounts of several other dialkyl thio- 
sulphinates [RS (O)SR'; R and R' are allyl, methyl and 
propyl] and complex sulphinyl components including the 
antithrombotic ajoenes. Garlic when processed by steam 
distillation, yields an oily mass consisting of diallyl, methyl 
allyl, dimethyl, and allyl 1-propenyl oligosulphides - all 
originating from the thiosulphinates (20). The steam dis- 
tilled essential oil, though lacking most of the antibacteri- 
al and antithrombotic activity (with the exception of com- 
ponents such as diallyl trisulphide, allyl methyl trisulphide 
and other paraffinic polysulphides which show antiplatelet 
activity in vitro), has been found to possess other equally 
interesting biological properties, such as antitumor and 
antioxidant effects (21,22). When garlic is subjected to cold 
aging process, besides oil-soluble organosulphur com- 
pounds (diallyl sulphide, diallyl disulphide, methyl allyl 
trisulphide and other polysulphides, ajoene, dithiins etc) 
major water-soluble organosulphur compounds, such as S- 
allyl cysteine, S-allyl mercaptocysteine, and several sul- 
phur-containing amino acids are produced. S-allyl cysteine 
and S-allyl mercaptocysteine have been shown to be anti- 
cancer in animals (23), and to provide protection against 
liver damage (24).  
 Role of adenosine vis-a-vis other components 
One of the ingredients of garlic is adenosine. About half 
of the antiplatelet activity of garlic has been attributed to 
adenosine (16). As adenosine is water soluble, a part of 
the antiaggregatory effects observed with the aqueous 
extracts of garlic and onion (and possibly ginger) in vitro 
(11) could be due to adenosine present in the extracts. To 
clarify the mode of action of adenosine on platelet aggre- 
gation and AA metabolism in platelets, we used commer- 
cially available adenosine for this purpose. Adenosine 
abolished AA- and collagen-induced aggregation at 1-2 
MM and 10 MM respectively. However, adenosine (i) did 
not inhibit the formation of thromboxane and 12-lipoxy- 
genase products from labelled AA in platelets even when 
used up to 990 MM; (ii) did not inhibit the release of labelled 
AA from platelet phospholipids [which were prelabelled 
with (14C)AA] on stimulation with calcium ionophore 
A23187 at 50, 200 and 560 MM; (iii) did not inhibit 
ionophore A23187-induced aggregation even up to 1 MM 
concentration (14). As the reactions in steps (i) to (iii) were 
found to be influenced by garlic extracts (aqueous and   
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organic), it was concluded that garlic contains also com- 
ponents, other than adenosine, which contribute to 
antiplatelet activity (13,14). Our observations with adeno- 
sine are similar to those of other who have reported that 
adenosine and allicin present in garlic inhibited platelet 
aggregation without altering AA metabolism in platelets 
(16). Polysulphides, such as diallyl trisulphide (25), 
dimethyl trisulphide (16) and methyl allyl trisulphide (26) 
were shown to be antiaggregatory and altered AA metab- 
olism (16,25,26). 
What all these would mean in an in vivo situation (that is, 
after consumption of garlic). In aggregation studies 
employing whole blood, adenosine was ineffective proba- 
bly because it is taken up by erythrocytes which have a 
highly active nucleoside transport system and adenosine 
deaminase activity (ADA) of about 0.2 pmolar units per 
ml of cells (27). This would correspond to whole body ery- 
throcyte ADA activity capable of degrading 135 mg adeno- 
sine per min. Other tissues such as liver and the intestinal 
mucosa have a high ADA activity. This means that adeno- 
sine would be poorly absorbed from the intestinal tract, 
and whatsoever reaches the blood would not survive more 
than a few minutes after absorption. Similarly, allicin was 
not traceable in blood after administration of garlic (28). 
Because of its chemical nature as a strong oxidizing agent 
and reacting rapidly with sulphydryl group of cysteine, it 
is likely that it renders itself ineffective by reacting with the 
peptides containing cysteine in the intestine and produc- 
ing S-allyl mercaptocysteine. Nevertheless, as garlic and 
garlic products have been found to show effects in animals 
and humans, it seems reasonable that other products 
derived from allicin and other thiosulphinates (alkyl poly- 
sulphides, dithiins, ajoene) could reach circulation and 
body tissues since they are non-reactive (non-oxidative) 
and are lipid soluble. May be, it is these compounds which 
produce some of the medicinal effects. However, it can 
not be excluded that some hitherto unknown metabolite(s) 
derived from allicin with biological activity might be dis- 
covered in future. The active principles identified in garlic 
and onion are shown in Table 1. 
Table 1. Active principles of garlic and onion. 
Antiplatelet 
Garlic:  
alliin          
allicin  
allyl 1,5-hexadienyl trisulphide  
allyl methyl trisulphide 
S-allyl 2-propene thiosulphinate  
ajoene 
diallyl disulphide  
diallyl trisulphide        
1,5-hexadienyl trisulphide 
methyl allyl trisulphide        
2-vynil 1,3-dithiene  
3-vinyl 1,2-dithiene      
Onion:     
adenoside       
alliin  
l-(methyl sulphynil)-propyl methyl disulphide                
9,10,13-trihydroxy-ll-octadecenoic acid         
9,12,13-trihydroxy-10-octadecenoic acid                 
trans-5-ethyl-4,6,7-trithia-2-decene-4-oxide       






diallyl disulphide  




methyl cysteine sulphoxide  
propyl allyl disulphide                     
propyl cysteine sulphoxide           
Onion:  
cycloalliin  
Blood sugar, insulin 
Garlic:  
allicin  
diallyl disulphide . 
Onion:  
allyl propyl disulphide 
Blood lipids, cholesterol 
Garlic:  
alliin                           
allicin                                   
allyl propyl disulphide       
diallyl disulphide                               
S-methyl-L-cysteine sulphoxide 
(From: Jos Kleijnen et al., Br J Clin Pharmacol 28: 535- 
544, 1989) 
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• Onion (Allium cepa) 
An oily extract of onion inhibits both the cyclooxygenase 
and 12-lipoxygenase in platelets, and inhibits also platelet 
aggregation induced by ADP, adrenaline and AA (11,12). 
The compounds inhibiting the two enzymes have been 
identified (29). 
Crude ethanolic onion extracts have been shown to pre- 
vent allergen-induced bronchoconstriction in laboratory 
animals and humans. This interesting observation has pro- 
moted search for the chemicals which bring about this 
effect. More than 150 chemicals have been isolated from 
onion. An a,p-unsaturated thiosulphinate and six unsat- 
urated a-sulphinyldisulphides with biological activity have 
been characterized. These compounds have been collec- 
tively termed "cepaenes". They strongly inhibit cyclooxy- 
genase in the microsomes from sheep seminal vesicular 
gland and also 5-lipoxygenase (5-LO) of porcine leuko- 
cytes (29). Alk(en)ylsulphinithioic acid esters are report- 
ed to inhibit histamine release, leukotriene and throm- 
boxane biosynthesis in vitro and prevent PAF- and aller- 
gen-induced bronchial obstruction in vivo (30). Recently, 
a compound structurally related to a-sulphinyldisulphides 
and identified as l-(methylsulphinyl)-propyl methyl disul- 
phide has been isolated from onion. This compound 
inhibits collagen-induced platelet aggregation. As it does 
not occur as such in onion, it is rather formed by an inter- 
action of thiopropanal-S-oxide and methyl sulphinic acid 
produced when onion is crushed (31). Several possible 
therapeutic benefits of onion include: retards blood clot- 
ting, thins the blood, boosts beneficial HDL cholesterol, 
lowers total blood cholesterol (all suggesting onion's 
potential as a multifaceted heart-blood medicine), regu- 
lates blood sugar etc. 
• Ginger (Zingiber officinale) 
Ginger is used in folkmedicin, and is a popular food spice. 
It has many therapeutic uses. It is mentioned in British 
Pharmacopoea as a carminative. It occupies an important 
place in Ayurvedic and Graeco-Arabic (Tibb) systems of 
medicine where, among other things, it is recommended 
against rheumatism (32). 
Chemically ginger, as one may expect, contains several 
classes of compounds. The chemical composition of dried 
ginger is as follows: starch 40-60%, proteins 10%, fats 10%, 
firbes 5%, inorganic material 6%, residual moisture 10%, 
and essential oil (oleoresin) 1-4%. In all more than 200 dif- 
ferent volatile substances have been characterized in the 
essential oil fraction wherein the pharmacologically active 
compounds are to be found. 
Ginger, its extracts and fractions thereof have been shown 
to inhibit platelet aggregation both in vitro (33) and ex vivo 
(34). The last one is related to an incidental observation 
by Dr. Dorso (the donor of blood) that only one-time con- 
sumption the previous evening of a large quantity of an 
excellent marmalade (Ginger with Grapefruit, Crabtree 
and Evelyn, London) whose major ingredient (15%) was 
ginger produced inhibition of AA-induced platelet aggre- 
gation which returned to normal after about a week time. 
We and others have shown that ginger strongly inhibits 
prostaglandin synthesis (11,33,35). Even some of the com- 
ponents identified in ginger were more potent than 
indomethacin in inhibiting prostaglandin synthesis (35). 
Ginger contains also several 5-lipoxygenase (5-LO) 
inhibitors (36). Ginger consumption resulted in reduced 
formation of thromboxane in human blood (37). Ginger 
has been shown to ameliorate symptoms of pain and 
swelling in musculo-skeletal diseases, which is brought 
about, at least, by its inhibition of cyclooxygenase and 5- 
LO pathways (that is, a dual inhibitor of AA metabolism) 
(38-40). In addition, ginger was found to exert abortive and 
prophylactic effects in migraine headache (41). 
Ginger is known to possess antihistamic and antioxidant 
properties (32). The role of free radicals as endogenous 
histamine liberators has attracted attention. Significant 
peroxidation of membrane lipids could have damaging 
effects on membrane fluidity and cell compartmentaliza- 
tion with a consequent leakage of endocellular compounds, 
including histamine. In this context, AA may be consid- 
ered to be a source of free radicals. Release of histamine 
from mast cells dependent on the generation of PG- 
endoperoxides from AA has been demonstrated (42). The 
release of histamine from mast cells by metabolitically acti- 
vated AA is not associated with a significant leakage of 
LDH; this may suggest it to be an exocytotic secretory 
process. As this process was blocked by reduced glu- 
tathione, D-mannitol, and by lipoxygenase and cyclooxy- 
genase pathway inhibitors, and was not reproduced by AA 
and by the end-products of the AA cascade, it may be sug- 
gested that free radical intermediates generated in the 
metabolic activation of AA are involved in mast cell hist- 
amine release (42,43). 
• Clove (Syzygium aromaticum) 
Clove, a pungent aromatic dried flower bud of myrtaceous 
tree, is frequently used in spice mixtures in the Indian sub- 
continent. Clove is also used as a crude drug for home 
medicine. It is reputed to be an aromatic stomachic in tra- 
ditional medicine. There have been reported only a few 
pharmacological studies with clove; its active principles 
possess cholagogue effects (44). We have observed that an   
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ethereal extract of clove (oil of cloves) inhibits strongly 
platelet aggregation, an effect which is largely mediated by 
reduced prostanoid synthesis (45). Further, we have iso- 
lated and characterized eugenol and acetyl eugenol, two 
potent antiplatelet compounds present in the oil of cloves. 
They inhibit AA-, adrenaline- and collagen-induced 
platelet aggregation; they are more potent in inhibiting 
aggregation induced by the first two agonists. Their 
inhibitory effect was reversible. These components behave 
antiaggregatory, at least, by a combination of two effects: 
(i) inhibition of platelet thromboxane formation, and (ii) 
increased formation of 12-lipoxygenase (12-LO) product 
(12-HPETE) which has been shown to be antiaggregato- 
ry, and inhibits platelet thromboxane formation. 
Furthermore, plasma proteins (especially albumin) may 
act as a 'condiut' diverting free AA from the cyclooxyge- 
nase to the lipoxygenase pathway, i.e., it ensures increased 
production of 12-lipoxygenase products (46,47). This might 
explain why relatively lower amounts of these compounds 
inhibit AA-induced aggregation in contrast to the amounts 
needed for inhibition of thromboxane synthesis in washed 
platelets. This observation with platelets in plasma (aggre- 
gation experiments) and washed platelets (AA metabolism 
studies) becomes more interesting if one considers that in 
aggregation experiments plasma proteins are very likely to 
bind these compounds, thus lowering their effective con- 
centrations considerably. The two compounds were more 
potent than aspirin in inhibiting aggregation induced by 
AA, adrenaline and collagen. In AA-induced aggregation 
eugenol was on par with indomethacin (48). 
Eugenol is a phenolic compound, and several phenolic 
cyclooxygenase inhibitors have been shown to be anti- 
inflammatory in animal models. The best examples are 
served by eugenol and curcumin (49,50). In fact, natural- 
ly occurring phenolic compounds are reputed in the folk- 
lore as "counter irritants". For centuries they have been 
used in plasters, liniments, poultices and rubs for their anti- 
inflammatory effects. Properties like cyclooxygenase inhi- 
bition, antioxidation and free radical scavanging might 
contribute to their anti-inflammatory effects. A structure- 
activity relationship for phenolic compounds in relation to 
cyclooxygenase inhibition has been reported (51). 
• Turmeric (Curcuma longa L.) 
Curcuma longa is a perennial herb widely cultivated in 
tropical regions of Asia. Its dried rhizome (turmeric pow- 
der) is used for imparting colour and flavour to food. 
Turmeric is used for medicinal purposes. There major com- 
ponents, l,7-bis(4-hydroxy-3-methoxyphenil)-l,6-hepta- 
diene-3,5-dione (curcumin), p,p'-dihydroxydicinnamoyl- 
methane, and p-hydroxycinnamoyl (feruloyl)methane 








most important fraction. This substance is effective in 
reducing inflammation in animals and provides relief in 
arthritis in humans (52). In a short double-blind cross-over 
clinical trial involving 18 patients with confirmed rheuma- 
toid arthritis, curcumin was found to produce significant 
improvement of symptoms such as, morning stiffness, 
walking time, and joint swelling following two weeks of 
therapy with an oral dose of 120 mg per day in all the 
patients (53). It was demonstrated to show hypercholes- 
terolemic effects in rats (54). It has been shown to possess 
antihepatotoxic properties (55). It lowered blood sugar in 
a patient with diabetes (56). Curcuma powder has been 
reported to increase mucin content of gastric juice in rab- 
bits (57). Thus, it may prove useful in providing protection 
to gastric mucosa against irritants. Curcumin has been 
shown to have strong antioxidant properties (58). It has 
been demonstrated to be an effective antimutagen in vitro 
against several environmental and standard mutagens and 
carcinogens that require metabolic activation for their 
activity. Curcumin provides protection against lipid per- 
oxide-induced DNA damage (59). Turmeric fed at 0.5% 
of the diet and above inhibited benzo( oc)pyrene- and 3- 
methylcholanthrene-mediated mutagenicity. Water solu- 
ble compounds from turmeric possess antioxidant/anti- 
clastogen and anti-promoter properties, and provide pro- 
tection against mutagenicity of direct-acting carcinogens 
as well as in benzo(oc) pyrene-induced genotoxicity and 
carcinogenicity (60). Turmeric and its active component, 
curcumin, have been reported to provide symptomatic 
relief in patients with external cancerous lesions (61). 
Topical application of curcumin strongly inhibited 12-O- 
tetradecanoylphorbol-13-acetate (TPA)-induced 
ornithine decarboxylase activity, DNA synthesis and tumor 
promotion in mouse skin (62). The inhibitory effect of cur- 
cumin in TPA-induced tumor promotion in mouse epi- 
dermis was found parallel to its inhibitory effect on TPA- 
induced epidermal inflammation and epidermal lipoxyge- 
nase and cyclooxygenase activities (62). The anticarcino- 
genicity of curcumin, which has been shown to be a potent 
inhibitor of the genotoxicity of various environmental 
mutagens/carcinogens, is probably mediated by its 
inhibitory effect on DNA-carcinogen adduct formation 
(63). It appears that the anticarcinogenicity is mediated by 
a series of mechanisms. Thus populations, like those in 
India, which include in their daily diet considerable 
amounts of turmeric [ca. 2-2.5 g per person per day for an 
average individual of 60 kg body weight (WHO/FAO 
Report 1974); the dry rhizome contains about 3-5% cur- 
cumin] (64), may be protected from the damaging effects 
of several mutagens/carcinogens present in the diet (65), 
besides those originating from occupational sources and 
life-style (tobacco habits) (66). When turmeric is used as 
a medication, it may be taken in doses up to 5 g daily. 
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Further, curcumin is reported to be non-toxic even at 100 
times the usual intake (67). 
The three active components of turmeric, including cur- 
cumin, were found to possess anticoagulation activity. 
Curcumin at doses between 25 and 100 mg/kg (i.p.) inhib- 
ited collagen- and adrenaline-induced aggregation of 
Tosta- 
cyclin synthesis in rat thoracic aorta. As collagen-induced 
aggregation is associated with increased production of 
TxA2> it may by assumed that curcumin inhibits aggrega- 
tion by reducing thromboxane synthesis. 
In our studies, ethereal extract from turmeric was found 
to exert influence at several steps of the AA cascade in 
platelets. Thus, this spice, besides inhibiting cyclooxyge- 
nase, inhibited the incorporation of AA into platelet phos- 
pholipids, and also inhibited the release of (^C)AA from 
labelled platelets on stimulation with A23187 (68)(ref 13 
and 14 for comparsion with garlic). It would, therefore, be 
interesting to examine if these effects on the AA cascade 
were common to other cell types or were specific for blood 
plateles. If incorporation and release of AA were also 
inhibited by turmeric in other cells (e.g., PMNs) it might 
explain its anti-inflammatory effects. For a concise infor- 
mation on the pharmacological properties of Curcuma 
longa (turmeric) the reader may refer to a recent review 
(69). 
SOME LESS KNOWN SPICES 
• Spices, such as omum (Trachyspermum ammi), 
asafoetida (Ferula foetida) and fenugreek (Trigonella 
foenumgraecum) are used less frequently, and in relative- 
ly small quantities in culinary practice in the Indian sub- 
continent. Cumin (Cuminum cyminum) is used though in 
relatively higher amounts compared to the three men- 
tioned above, but not to the extent of other spices. In 
Ayurveda, omum is described to possess antispasmodic 
properties, and is prescribed in stomach trouble. In India 
it is a common practice to give women post parturition 
(after childbirth) a decoction of omum seeds. Cumin is 
known to provide ameliorative effects in stomach disor- 
ders. Organic extracts of both the spices inhibites AA- 
induced aggregation and production of TxB2 from exoge- 
nous AA and in AA-labelled platelets (68,70). Cumin 
extract inhibited also collagen- and adrenaline-induced 
aggregation (68). 
Asafoetida is an odorous resin which is used only in very 
small amounts (milligram quantities) in food making 
because of its strong flavour and bitter taste. The essential 
oil isolated from the resin has been shown to have firbri- 
nolytic and hypocholesterolemic properties. Fenugreek 
seeds and also its leaves are used as spice. Especially the 
seeds are known to provide relief in diarrhoea and gas- 
trointestinal spasms. In rats, feeding with fenugreek-sup- 
plemented diet for five weeks improved clinical parame- 
ters, such as hyperglycemia, free fatty acids, cholesterol 
and triglycerides to normal values in experimental diabets 
(71). 
COMCLUSIOMS AND PERSPECTIVES 
• The food species that we have studied, and also 
several others form a part of the diet of large populations 
of Asia and other regions of the world. Their regulatory 
effects on the eicosanoid production may suggest that they 
might provide protection against diseases in which elevat- 
ed levels of eicosanoids have been reported. Many spices 
(e.g., ginger, garlic, onions, clove, hot peppers) contain 
antioxidants which might potentiate the effects of physio- 
logically significant dietary antioxidants, such as selenium, 
and vitamins A, C and E. These micronutrients, as is well 
recognized, provide synergistic multilevel defense system 
againts free radical injury and lipid peroxidation. Several 
reports have appeared showing an inverse relationship 
between the levels of anti-oxidants in the blood and 
ischaemic heart disease. Besides, a number of antioxidants 
are known to possess anti-carcinogenic properties. Thus, 
spices (e.g. turmeric) and their components may supple- 
ment, facilitate and/or enhance the activity of natural 
antioxidant systems protecting against the oxidative stress 
presumbly involved in the multistep process of carcino- 
genesis. In addition, scientific confirmation of the medic- 
inal properties of food constituents as are found in the folk- 
lore may contribute to the development of dietary supple- 
ments (fish oil supplement, various garlic preparations on 
the market) and may also provide clues to the develop- 
ment of useful drugs. Futhermore, guided by the observa- 
tion with the Eskimos who ingest large amounts of omega- 
3 fatty acids, which do not seem to cause them any harm, 
rather protect them from cardiovascular disorders and 
other chronic diseases, it would be of interest to pursue 
epidemiological survey of populations which consume 
spices regularly with regard to the prevalence of diseases 
typical of the the industrialized societies. ; 
The enthusiasm about spices and their possible protective 
role in coronary heart disease (CHD) may be lessened 
when one takes into account the reports of epidemiologi- 
cal studies made on populations consuming spices with 
regard to prevalence of CHD in such populations. High 
rates of CHD in populations of South Asian origin were 
reported from Singapore, South Africa and Trinidad in 
1950s. Similar finding were reported from U.K. for popu-   
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lations of South Asian origin in 1971. The high rates of 
CHD in Asian immigrants could not be explained on the 
basis of well-known risk factors such as plasma total cho- 
lesterol and smoking habbits. Non-insulin dependent dia- 
betes is present in about 20% of South Asian men and 
women aged over 40 years in the United Kindom, com- 
parted with about 5% of Europeans. Similar prevalence 
rates have been reported for other overseas South Asian 
populations and for an urban population in South India. 
A strong etiological predictor is a combination of genetic 
components, non-insulin dependent diabetes and obesity. 
Insulin resistance is associated with a particular type of 
obesity in which a high portion of body fat is deposited 
intra-abdominally. This would lead to physiological dis- 
turbances including hyperinsulinaemia, hypertriglyceri- 
daemia, low concentrations of plasma high density lipopro- 
tein cholesterol and hypertension (72). In these popula- 
tions, spiced food consumption is a common practice. 
Should it be assumed then that spices do not have any pro- 
tective effect? In answer, a point of caution we would like 
to make here. The way spices are used in food preparation 
in Northern India and Pakistan (and this may be so for the 
entire Indian sub-continent) may not be a healthy practice 
at all. During cooking spices are almost always exposed to 
high temperatures (frying) for periods long enough which 
would destroy the active/useful components some of which 
are anti-oxidants and modulate the arachidonic acid path- 
way. Such a cooking practice is likely to obscure results of 
any future epidemiological study of populations consum- 
ing spices if they use spices in cooking the way it is prac- 
tized in the Indian sub-continent, and occurrence of dis- 
eases mediated by eicosanoids. In contrast, in Greece 
CHD is minimal though people eat fat-laden meat and 
smoke relatively much. But they love to eat peppers, onion, 
garlic and spices, besides fresh fruits providing physiolog- 
ically important antioxidants. Furthermore, consumption 
of olive oil may have additional benefits. The same is true 
for Italy and Spain. 
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